Extended indication Antagonist antistollingsmiddelen, zowel DOACs als LMWH
Therapeutic value Possible added value
Total cost 1,675,000.00
Registration phase Clinical trials

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information